Ms. Camila Canaán-Haden | Biomedical research | Best Researcher Award
PhD student, Center for Genetic Engineering and Biotechnology (CIGB)
Camila Canaán-Haden Ayala is a Cuban researcher specializing in cancer immunotherapy. She works at the Center for Genetic Engineering and Biotechnology (CIGB), focusing on developing therapeutic cancer vaccines and recombinant antigen production. Her expertise includes immune response evaluations using ELISA, FACS, ELISPOT, and cytokine assays in various models. She has contributed to COVID-19 clinical trials and vaccine development, including the Abdala vaccine. Camila has undertaken multiple international research fellowships in Italy, Spain, France, and Mexico. Her work aims to improve immunotherapeutic strategies against cancer by targeting immune checkpoints and optimizing vaccine efficacy.
Profile
M Limonta-Fernández, G Chinea-Santiago, AM Martín-Dunn, …
Title: An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
Year: 2022
Citation: 63
LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, …
Title: In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2
Year: 2021
Citation: 15
YA Fleites, J Aguiar, Z Cinza, M Bequet, E Marrero, M Vizcaíno, I Esquivel, …
Title: HeberNasvac, a therapeutic vaccine for chronic hepatitis B, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 postexposure prophylaxis
Year: 2021
Citation: 10
LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, …
Title: In-solution buffer-free digestion for the analysis of SARS-CoV-2 RBD proteins allows a full sequence coverage and detection of post-translational modifications in a single ESI
Year: 2021
Citation: 8
Y Morera-Díaz, C Canaán-Haden, J Sánchez-Ramírez, …
Title: Active immunization with a structurally aggregated PD-L1 antigen breaks T and B immune tolerance in non-human primates and exhibits in vivo anti-tumoral effects in
Year: 2023
Citation: 4
D Vázquez-Blomquist, M Bequet-Romero, Y Mendoza-Marí, G Lemos, …
Title: Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood
Year: 2022
Citation: 4
EM Idelsis, PE Jésus, DR Yaquelin, VB Dania, BR Mónica, BR Lisandra, …
Title: A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial
Year: 2021
Citation: 4
C Canaán-Haden, J Sánchez-Ramírez, R Martínez-Castillo, …
Title: Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys
Year: 2025
Citation: N/A
Y Morera, M Bequet-Romero, F Hernández-Bernal, I González-Moya, …
Title: Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Year: 2023
Citation: N/A